PH12019500758A1 - Pharmaceutical compositions and methods for the treatment of cancer - Google Patents

Pharmaceutical compositions and methods for the treatment of cancer

Info

Publication number
PH12019500758A1
PH12019500758A1 PH12019500758A PH12019500758A PH12019500758A1 PH 12019500758 A1 PH12019500758 A1 PH 12019500758A1 PH 12019500758 A PH12019500758 A PH 12019500758A PH 12019500758 A PH12019500758 A PH 12019500758A PH 12019500758 A1 PH12019500758 A1 PH 12019500758A1
Authority
PH
Philippines
Prior art keywords
promoter
methods
subject
pharmaceutical compositions
inhibitor
Prior art date
Application number
PH12019500758A
Other languages
English (en)
Inventor
Steven Hoffman
Original Assignee
Tyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/351,966 external-priority patent/US10272068B2/en
Application filed by Tyme Inc filed Critical Tyme Inc
Publication of PH12019500758A1 publication Critical patent/PH12019500758A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
PH12019500758A 2016-11-15 2019-04-08 Pharmaceutical compositions and methods for the treatment of cancer PH12019500758A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/351,966 US10272068B2 (en) 2012-01-17 2016-11-15 Pharmaceutical compositions and methods
PCT/US2017/061682 WO2018093820A1 (en) 2016-11-15 2017-11-15 Pharmaceutical compositions and methods for the treatment of cancer

Publications (1)

Publication Number Publication Date
PH12019500758A1 true PH12019500758A1 (en) 2019-07-24

Family

ID=60570232

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019500758A PH12019500758A1 (en) 2016-11-15 2019-04-08 Pharmaceutical compositions and methods for the treatment of cancer

Country Status (12)

Country Link
EP (1) EP3541411A1 (enExample)
JP (2) JP2019537608A (enExample)
KR (2) KR20230003314A (enExample)
CN (1) CN110167580A (enExample)
AU (1) AU2017361080A1 (enExample)
BR (1) BR112019009799A2 (enExample)
CA (1) CA3040922A1 (enExample)
EA (1) EA201991192A1 (enExample)
IL (1) IL266486A (enExample)
MX (1) MX2019005450A (enExample)
PH (1) PH12019500758A1 (enExample)
WO (1) WO2018093820A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220098682A (ko) 2019-05-14 2022-07-12 타임, 인크. 암을 치료하기 위한 조성물 및 방법
EP4045027A1 (en) * 2019-10-15 2022-08-24 Tyme, Inc. Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer
CN115515575A (zh) * 2020-01-17 2022-12-23 迪美公司 用于调节癌症的酪氨酸衍生物
CN111358777A (zh) * 2020-02-24 2020-07-03 军事科学院军事医学研究院环境医学与作业医学研究所 一种提高外周血单个核细胞线粒体功能的方法和应用
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
EP4255920A4 (en) * 2020-12-02 2024-10-23 Hoffman Technologies LLC COMPOSITIONS AND METHODS FOR MODULATING CANCER IN NON-HUMAN MAMMALS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225435A (en) 1990-05-18 1993-07-06 Yale University Soluble melanin
WO2006032299A1 (en) * 2004-09-24 2006-03-30 Susanna Miettinen Use of inhibitors of 24-hydroxylase in the treatment of cancer
US20060078494A1 (en) * 2004-09-24 2006-04-13 Sapphire Therapeutics, Inc. Use of inhibitors of 24-hydroxylase in the treatment of cancer
US20130183263A1 (en) * 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
WO2013109610A1 (en) * 2012-01-17 2013-07-25 Steven Hoffman Pharmaceutical compositions and methods
US8481498B1 (en) * 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Also Published As

Publication number Publication date
CN110167580A (zh) 2019-08-23
WO2018093820A1 (en) 2018-05-24
CA3040922A1 (en) 2018-05-24
AU2017361080A1 (en) 2019-05-02
IL266486A (en) 2019-07-31
EP3541411A1 (en) 2019-09-25
BR112019009799A2 (pt) 2019-08-06
EA201991192A1 (ru) 2019-10-31
KR20230003314A (ko) 2023-01-05
KR20190084291A (ko) 2019-07-16
JP2019537608A (ja) 2019-12-26
MX2019005450A (es) 2019-07-04
JP2023018029A (ja) 2023-02-07

Similar Documents

Publication Publication Date Title
PH12014501639B1 (en) Pharmaceutical compositions and methods
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
PH12020551923A1 (en) Methods and compositions for treating cancer
PH12022551013A1 (en) Pyridazinones as parp7 inhibitors
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2020013649A (es) Composiciones y metodos para inhibir la actividad de la arginasa.
EP4234551A3 (en) Pyridazinones as parp7 inhibitors
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
MX2017010595A (es) Métodos, composiciones, y equipos para tratamiento de cáncer.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2018002344A (es) Metodo para tratar el cancer.
MX2018007266A (es) Combinaciones para el tratamiento del cancer.
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2019013862A (es) Terapia de combinacion.
MX2022002699A (es) Lurbinectedina en el tratamiento del mesotelioma maligno.
MX2020001727A (es) Terapia de combinacion.
MX2021012418A (es) Compuestos heterociclicos y sus usos.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer